UNCONTROLLED WHEN PRINTED
Introduction
  • A non-depolarising neuromuscular blocking agent
  • Due to weak vagolytic action, a slight rise in pulse rate and MAP may be expected.
  • Onset: 2-3 min, peak 8-10 min.
  • Duration 30 min dose dependant
Indications
  • To facilitate paralysis
  • Maintain paralysis 
Contraindications
  • Hypersensitivity
Precautions / Notes
  • Sedatives to be administered prior to Rocuronium Bromide unless patient hemodynamically unstable and performing crash intubation
  • Continuous SpO2 and EtCO2  monitoring is a high priority
  • Patients with Myasthenia Gravis should be given smaller doses and monitored carefully due to the potential of increased degree of neuromuscular block.
  • Keep refrigerated at 2-8°C.
  • Crash intubation preferred over Suxamethonium
Management
Critical Care Paramedic only

Adult/Paediatric:

  • IV/IO
    • Induction: 1.2mg/kg
      • Initial dose: 0.6mg/kg (usually 50mg in adults) post Suxamethonium dose only
      • Maintenance : 0.1-0.2mg/kg repeat PRN
    • Infusion: 1.0mg/kg/hr
      • Dilute 100mg in 10ml up to 100mg in 50ml with normal saline
Dose 10kg 20kg 30kg 40kg 50kg 60kg 70kg 80kg 90kg 100kg
1mg/kg/hr 5ml/hr 10ml/hr 15ml/hr 20ml/hr 25ml/hr 30ml/hr 35ml/hr 40ml/hr 45ml/hr 50ml/hr
Special Considerations
  • Slight increase in pulse
  • Slight increase in mean arterial pressure

References
References
Presentation
50mg in 5ml ampoule

Presentation image

Colour assist:

Document Control


Directorate
Clinical Services

Responsible Manager
Head of Clinical Services

Date of Issue

Date of Expiry

St John WA © Copyright 2020. All Rights Reserved

Privacy Policy | Copyright Statement & Disclaimer